Abstract:Non-alcoholic fatty liver disease (NAFLD) is a pathological condition which is strongly correlated with fat accumulation in the liver that has become a major health hazard globally. So far, limited treatment options are available for the management of NAFLD and partial agonism of Farnesoid X receptor (FXR) has proven to be one of the most promising strategies for treatment of NAFLD. In present work, a range of validated predictive cheminformatics and molecular modeling studies were performed with a series of 3-benzamidobenzoic acid derivatives in order to recognize their structural requirements for possessing higher potency towards FXR. 2D-QSAR models were able to extract the most significant structural attributes determining the higher activity towards the receptor. Ligand-based pharmacophore model was created with a novel and less-explored open access tool named QPhAR to acquire information regarding important 3D-pharmacophoric features that lead to higher agonistic potential towards the FXR. The alignment of the dataset compounds based on pharmacophore mapping led to 3D-QSAR models that pointed out the most crucial steric and electrostatic influence. Molecular dynamics (MD) simulation performed with the most potent and the least potent derivatives of the current dataset helped us to understand how to link the structural interpretations obtained from 2D-QSAR, 3D-QSAR and pharmacophore models with the involvement of specific amino acid residues in the FXR protein. The current study revealed that hydrogen bond interactions with carboxylate group of the ligands play an important role in the ligand receptor binding but higher stabilization of different helices close to the binding site of FXR (e.g., H5, H6 and H8) through aromatic scaffolds of the ligands should lead to higher activity for these ligands. The present work affords important guidelines towards designing novel FXR partial agonists for new therapeutic options in the management of NAFLD. Moreover, we relied mainly on open-access tools to develop the in-silico models in order to ensure their reproducibility as well as utilization.

Activity Screening of Fatty Acid Mimetic Drugs Identified Nuclear Receptor Agonists

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Farnesoid X receptor modulators 2014-present: a patent review

Pose Filter-Based Ensemble Learning Enables Discovery of Orally Active, Nonsteroidal Farnesoid X Receptor Agonists

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Virtual Screening of Potentially Endocrine-Disrupting Chemicals Against Nuclear Receptors and Its Application to Identify PPARγ-bound Fatty Acids

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.

Structure Optimization of 12β-O-γ-Glutamyl Oleanolic Acid Derivatives Resulting in Potent FXR Antagonist/Modulator for NASH Therapy

Computational study of novel natural agonists targeting farnesoid X receptor

Biomimetic Total Synthesis and the Biological Evaluation of Natural Product (-)-fargesone A As a Novel FXR Agonist

Discovery of New Non‐Steroidal Farnesoid X Receptor Modulators Through 3D Shape Similarity Search and Structure‐Based Virtual Screening

Discovery of novel and selective farnesoid X receptor antagonists through structure-based virtual screening, preliminary structure-activity relationship study, and biological evaluation

Structural Optimization and Biological Evaluation of 1-Adamantylcarbonyl-4-phenylpiperazine Derivatives As FXR Agonists for NAFLD.

3D-QSAR and Molecular Dynamics Study of Isoxazole Derivatives to Identify the Structural Requirements for Farnesoid X Receptor (FXR) Agonists

The discovery of a new potent FXR agonist based on natural product screening

Pyrazolidine-3,5-dione Derivatives As Potent Non-Steroidal Agonists of Farnesoid X Receptor: Virtual Screening, Synthesis, and Biological Evaluation.

Discovery of Natural Products As Novel and Potent FXR Antagonists by Virtual Screening.

Discovery of New Non-Steroidal FXR Ligands Via a Virtual Screening Workflow Based on Phase Shape and Induced Fit Docking

Multi-model in silico characterization of 3-benzamidobenzoic acid derivatives as partial agonists of Farnesoid X receptor in the management of NAFLD

Virtual Screening and Experimental Validation Identify Novel Modulators of Nuclear Receptor RXRα from Drugbank Database.

Design, synthesis and structure-activity relationship studies of novel partial FXR agonists for the treatment of fatty liver